

PE anti-mouse/human CD11b Antibody

Catalog# / Size	101207 / 50 µg 101208 / 200 µg
Clone	M1/70
Regulatory Status	RUO
Other Names	αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype	Rat IgG2b, κ
Description	CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details

Verified Reactivity	Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity	Chimpanzee, Baboon, Rabbit
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	C57BL/10 splenocytes
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration	0.2 mg/mL
Storage & Handling	The CD11b antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested IHC - Verified
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F). Additional reported applications (for relevant formats of this clone) include: immunoprecipitation ^{1,4} , <i>in vitro</i> blocking ^{3,9,12} , depletion ^{2,8} , immunofluorescence microscopy ^{6,7,10} , immunohistochemistry of acetone-fixed frozen sections ^{5,11-13} , and spatial biology (IBEX) ^{35,36} . For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 101248).
Additional Product Notes	View more applications data for this product in our Scientific Poster Library .
Application References	<ol style="list-style-type: none"> 1. Springer T, <i>et al.</i> 1978. <i>Eur. J. Immunol.</i> 8:539. (IP) 2. Ault K and Springer T. 1981. <i>J. Immunol.</i> 126:359. (Deplete) 3. Springer TA, <i>et al.</i> 1982. <i>Immunol. Rev.</i> 68:171. (Block)

4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
5. Flotte TJ, et al. 1983. *Am. J. Pathol.* 111:112. (IHC)
6. Noel GJ, et al. 1990. *J. Clin. Invest.* 85:208. (IF)
7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
9. Brickson SJ, et al. 2003. *Appl Physiol.* 95:969. (Block)
10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
11. Hata H, et al. 2004. *J. Clin. Invest.* 114:582. (IHC)
12. Zhang Y, et al. 2002. *J. Immunol.* 168:3088. (IHC)
13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
15. Olver S, et al. 2006. *Cancer Research* 66:571. (FC)
16. Tan SL, et al. 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
17. Ponomarev ED, et al. 2006. *J. Immunol.* 176:1402. (FC)
18. Dzhagalov I, et al. 2007. *Blood* 109:1620. (FC)
19. Fazilleau N, et al. 2007. *Nature Immunol.* 8:753.
20. Rasmussen JW, et al. 2006. *Infect. Immun.* 74:6590. [PubMed](#)
21. Napimoga MH, et al. 2008. *J. Immunol.* 180:609. [PubMed](#)
22. Elqaraz-Carmon V, et al. 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
23. Kim DD, et al. 2008. *Blood* 112:1109. [PubMed](#)
24. Guo Y, et al. 2008. *Blood* 112:480. [PubMed](#)
25. Norian LA, et al. 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
26. Baumgartner CK, et al. 2010. *J. Immunol.* 184:573. [PubMed](#)
27. Charles N, et al. 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
28. Whiteland J, et al. 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
29. Weber GF, et al. 2014. *J Exp Med.* 211:1243. [PubMed](#)
30. Ashok A, et al. 2015. *Toxicol Sci.* 143:64. [PubMed](#)
31. Price PJ, et al. 2015. *J Immunol.* 194:1164. [PubMed](#)
32. Doni A, et al. 2015. *J Exp Med.* 212:905. [PubMed](#)
33. Ferreira R, et al. 2016. *J Infect Dis.* 213: 669 - 673. [PubMed](#)
34. Peterson VM, et al. 2017. *Nat. Biotechnol.* 35:936. (PG)
35. Radtke AJ, et al. 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
36. Radtke AJ, et al. 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Guo H, Cooper S, Friedman A, et al. 2017. *PLoS One.* 10.1371/journal.pone.0150809. [PubMed](#)
2. Chida J, et al. 2020. *PLoS Pathog.* 16:e1008823. [PubMed](#)
3. Guo Y, et al. 2021. *Exp Ther Med.* 353:21. [PubMed](#)
4. Ho YH, et al. 2019. *Cell Stem Cell.* 25:407. [PubMed](#)
5. Ying W, et al. 2019. *Cell Metab.* 29:457. [PubMed](#)
6. Kisielow J, et al. 2019. *Nat Immunol.* 1.286111111. [PubMed](#)
7. Li A, et al. 2020. *Oncol Lett.* 1.899305556. [PubMed](#)
8. Grigsby SM, et al. 2021. *Cancers (Basel).* 13:. [PubMed](#)
9. Kuo PC, et al. 2021. *Brain Commun.* 3:fcab187. [PubMed](#)
10. Zhao D, et al. 2021. *Innate Immun.* 27:533. [PubMed](#)
11. Nigam S, et al. 2020. *Mol Imaging Biol.* 22:685. [PubMed](#)
12. Hu K, et al. 2022. *J Extracell Vesicles.* 11:e12199. [PubMed](#)
13. Lei G, et al. 2016. *Antimicrob Agents Chemother.* 60: 1289 - 1297. [PubMed](#)
14. Viny AD, et al. 2019. *Cell Stem Cell.* 25:682. [PubMed](#)
15. Jones NM, et al. 2019. *BMC Cancer.* 1.127777778. [PubMed](#)
16. Wu N, et al. 2020. *Cell Rep.* 30:1129. [PubMed](#)
17. Bhatt K, et al. 2018. *mSphere.* 3:e00352. [PubMed](#)
18. Baryawno N et al. 2019. *Cell.* 177(7):1915-1932 . [PubMed](#)
19. Abels ER et al. 2019. *Cell Rep.* 28(12):3105-3119 . [PubMed](#)
20. Paris J et al. 2019. *Cell Stem Cell.* 25(1):137-148 . [PubMed](#)
21. Prajeeth C, et al. 2017. *J Neuroinflammation.* 10.1186/s12974-017-0978-3. [PubMed](#)
22. Schloss MJ, et al. 2022. *Nat Immunol.* 23:605. [PubMed](#)
23. Yan F, et al. 2022. *Cancer Discov.* 12:792. [PubMed](#)
24. Lee S, et al. 2021. *JCI Insight.* 6:. [PubMed](#)
25. Zhao X, et al. 2022. *Front Mol Biosci.* 9:786864. [PubMed](#)
26. Deng Y, et al. 2021. *Acta Pharmacol Sin.* 42:149. [PubMed](#)
27. Pan J, et al. 2021. *Mol Ther Nucleic Acids.* 26:970. [PubMed](#)
28. Li X, et al. 2015. *Proc Natl Acad Sci U S A.* 112:6080. [PubMed](#)
29. Zhang Y, et al. 2020. *Oncol Lett.* 1.053472222. [PubMed](#)
30. Dumas SJ, et al. 2021. *STAR Protocols.* 2(3):100523. [PubMed](#)
31. Zhang Z, et al. 2020. *J Immunol.* 204:3400. [PubMed](#)
32. Gonçalves NP, et al. 2017. *J Neuroinflammation.* 14:115. [PubMed](#)
33. Yamauchi T et al. 2018. *Cancer cell.* 33(3):386-400 . [PubMed](#)
34. Xiao X, et al. 2020. *J Hematol Oncol.* 0.597222222. [PubMed](#)
35. Elkabets M, et al. 2009. *J Immunol.* 182:4874. [PubMed](#)
36. Sauter M, et al. 2022. *iScience.* 25:103677. [PubMed](#)
37. Conforti A, et al. 2021. *PLoS One.* 16:e0259894. [PubMed](#)
38. Götz P, et al. 2022. *Int J Mol Sci.* 23:. [PubMed](#)
39. Adachi Y, et al. 2022. *Nat Commun.* 13:5117. [PubMed](#)
40. Forte E, et al. 2020. *J Cell Mol Med.* . [PubMed](#)
41. Earnest JT, et al. 2021. *Cell Reports.* 35(1):108962. [PubMed](#)
42. Jard T, et al. 2020. *Cell Stem Cell.* 27(4):646-662.e7. [PubMed](#)
43. Forte D, et al. 2020. *Cell Metab.* 32:829. [PubMed](#)
44. Coppo M, et al. 2016. *Nat Commun.* 7:12254. [PubMed](#)

45. Wang X, *et al.* 2016. PLoS Pathog. 12: 1005367. [PubMed](#)
46. Hiraishi Y, *et al.* 2018. Sci Rep. 8:18052. [PubMed](#)
47. Wu R, *et al.* 2019. J Cell Mol Med. 24:1684. [PubMed](#)
48. Llewellyn GN, *et al.* 2018. J Neurovirol. 24:192. [PubMed](#)
49. Sun Y *et al.* 2018. Cancer cell. 34(4):643-658 . [PubMed](#)
50. Shears RK, *et al.* 2020. J Allergy Clin Immunol. 145:1272. [PubMed](#)
51. Chen X, *et al.* 2021. Cell Death Differ. 28:1237. [PubMed](#)
52. Stolp B, *et al.* 2022. Cell Rep. 38:110387. [PubMed](#)
53. Craver BM, *et al.* 2020. Blood Adv. 4:312. [PubMed](#)
54. Price J, *et al.* 2015. Diabetes. 64: 3521 - 3531. [PubMed](#)
55. Kalucka J, *et al.* 2020. Cell. 764:180. [PubMed](#)
56. Turkowski K, *et al.* 2017. Glia. 10.1002/glia.23234. [PubMed](#)
57. Wiese A, *et al.* 2017. PLoS One. 10.1371/journal.pone.0184956. [PubMed](#)
58. Hengyou Weng *et al.* 2018. Cell stem cell. 22(2):191-205 . [PubMed](#)
59. Nakagawa S *et al.* 2017. Cell host & microbe. 22(5):667-677 . [PubMed](#)
60. Swidergall M, *et al.* 2019. Cell Rep. 28:423. [PubMed](#)
61. Ganeshan K *et al.* 2019. Cell. 177(2):399-413 . [PubMed](#)
62. LaFleur MW, *et al.* 2019. Nat Immunol. 20:1335. [PubMed](#)
63. Tsuchiya N, *et al.* 2020. Cell Reports. 29(1):162-175.e9.. [PubMed](#)
64. Fukushima T, *et al.* 2019. Cell Rep. 29:4144. [PubMed](#)
65. Joseph R, *et al.* 2021. Br J Cancer. 125:176. [PubMed](#)
66. Park JA, *et al.* 2021. J Hematol Oncol. 14:142. [PubMed](#)
67. Wang Y, *et al.* 2022. Acta Pharm Sin B. 12:262. [PubMed](#)
68. Zhou HF, *et al.* 2022. Front Pharmacol. 13:778755. [PubMed](#)
69. Chen F, *et al.* 2022. Evid Based Complement Alternat Med. 2022:1240242. [PubMed](#)
70. Xu F, *et al.* 2022. Cell Death Discov. 8:142. [PubMed](#)
71. Haugh KA, *et al.* 2021. eLife. 0.4166666666666667. [PubMed](#)
72. Perner C, *et al.* 2020. Immunity. 53(5):1063-1077.e7. [PubMed](#)
73. Endo Y, *et al.* 2020. FASEB J. 34:16086. [PubMed](#)
74. Diao N, *et al.* 2016. Sci Rep. 6:34672. [PubMed](#)
75. Huang L, *et al.* 2016. J Biol Chem. 291: 6232 - 6244. [PubMed](#)
76. Sharma S, *et al.* 2015. J Immunol. 194:5529. [PubMed](#)
77. Pan J, *et al.* 2020. J Neuroinflammation. 17:97. [PubMed](#)
78. Paraiso HC, *et al.* 2018. J Neuroinflammation. 0.694444444. [PubMed](#)
79. Pan W *et al.* 2017. Immunity. 47(2):284-297 . [PubMed](#)
80. Dey A *et al.* 2019. The EMBO journal. 38(7) pii: e100293. [PubMed](#)
81. Hammond TR, *et al.* 2019. Immunity. 50:253. [PubMed](#)
82. Wang C, *et al.* 2017. J Immunol. 10.4049/jimmunol.1700671. [PubMed](#)
83. Li K, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)
84. Hongu T, *et al.* 2022. Nat Cancer. 3:486. [PubMed](#)
85. Rogawski DS, *et al.* 2021. Nat Commun. 12:2792. [PubMed](#)
86. Trenevskaja I, *et al.* 2021. PLoS One. 16:e0249967. [PubMed](#)
87. Gordon RA, *et al.* 2020. PLoS One. 15:e0226396. [PubMed](#)
88. Zhang Z, *et al.* 2021. Oncoimmunology. 10:1912472. [PubMed](#)
89. Xiao Z, *et al.* 2015. Cancer Lett. 360:302. [PubMed](#)
90. Donley DW, *et al.* 2021. PLOS ONE. 16(5):e0250606. [PubMed](#)
91. Jassinskaja M, *et al.* 2021. Cell Reports. 34(12):108894. [PubMed](#)
92. Ratitong B, *et al.* 2021. Cell Reports. 35(7):109139. [PubMed](#)
93. An J, *et al.* 2017. Sci Rep.. 10.1038/s41598-017-13629-0. [PubMed](#)
94. Wang L, *et al.* 2017. Front Immunol.. 10.3389/fimmu.2017.01754. [PubMed](#)
95. Kunimoto H, *et al.* 2018. Cancer Cell. 33:44. [PubMed](#)
96. Parada-Kusz M, *et al.* 2018. Dis Model Mech. 11:. [PubMed](#)
97. Zhang S, *et al.* 2019. Mol Med Rep. 19:5377. [PubMed](#)
98. Shimokawa C *et al.* 2017. Immunity. 46(5):863-874 . [PubMed](#)
99. Riffelmacher T *et al.* 2017. Immunity. 47(3):466-480 . [PubMed](#)
100. Nakaya M, *et al.* 2017. J Clin Invest. 127:383. [PubMed](#)
101. Mayo L, *et al.* 2008. J Immunol. 181:92. [PubMed](#)
102. Cheng K, *et al.* 2021. Nat Commun. 12:2041. [PubMed](#)
103. Zheng Y, *et al.* 2022. Front Pharmacol. 12:816032. [PubMed](#)
104. Dane EL, *et al.* 2022. Nat Mater. 21:710. [PubMed](#)
105. Guo W, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)
106. Zhang X, *et al.* 2022. Cells. 11:. [PubMed](#)
107. Jin R, *et al.* 2020. Mol Cancer Ther. . [PubMed](#)
108. Nguyen TKT, *et al.* 2020. Am J Pathol. 286:190. [PubMed](#)
109. Gereke M, *et al.* 2012. J Vis Exp. 70: 4322. [PubMed](#)
110. Pang D, *et al.* 2015. Clin Transl Immunology. 4: e41. [PubMed](#)
111. Bertino P, *et al.* 2019. Oncoimmunology. 8:1601482. [PubMed](#)
112. Keshavarz M, *et al.* 2020. Virol J. 17:64. [PubMed](#)
113. He L, *et al.* 2019. iScience. 0.790972222. [PubMed](#)
114. Frazier T, *et al.* 2018. Adipocyte. 0.41875. [PubMed](#)
115. Deng Z, *et al.* 2017. Oncogene. 36:639. [PubMed](#)
116. Liu D *et al.* 2019. Immunity. 51(1):64-76 . [PubMed](#)
117. Anstine L, *et al.* 2017. J Am Heart Assoc.. 10.1161/JAHA.117.007097. [PubMed](#)
118. Kotaki R, *et al.* 2020. Sci Rep. 10:13554. [PubMed](#)
119. Wu L, *et al.* 2022. Theranostics. 12:842. [PubMed](#)
120. Ajina R, *et al.* 2021. Cancer Immunol Res. 9:386. [PubMed](#)
121. Jaworska K, *et al.* 2015. J Immunol. 194:325. [PubMed](#)
122. Chen Y, *et al.* 2015. PLoS One. 10: 0135217. [PubMed](#)
123. Li L, *et al.* 2015. J Am Soc Nephrol. 26: 2183-2197. [PubMed](#)
124. Souza COS, *et al.* 2021. iScience. 24(6):102548. [PubMed](#)

125. Hönes J, *et al.* 2017. *Sci Rep.* . 10.1038/s41598-017-15866-9. [PubMed](#)
126. Niemann J, *et al.* 2019. *Nat Commun.* 10:3236. [PubMed](#)
127. Hou M, *et al.* 2020. *Stem Cell Res Ther.* 11:55. [PubMed](#)
128. Mao FY, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:395. [PubMed](#)
129. Hildebrand KM, *et al.* 2021. *PLoS One.* 16:e0253864. [PubMed](#)
130. Du Y, *et al.* 2022. *Nat Commun.* 13:231. [PubMed](#)
131. Malekghasemi S, *et al.* 2020. *Cell Biol Int.* 44:2031. [PubMed](#)
132. Han D, *et al.* 2021. *J Immunol Res.* 6688053:2021. [PubMed](#)
133. Nguyen GT, *et al.* 2021. *iScience.* 24(8):102871. [PubMed](#)
134. Garg M, *et al.* 2021. *Cell Reports.* 34(6):108736. [PubMed](#)
135. Cao DY, *et al.* 2020. *J Biol Chem.* 295:1369. [PubMed](#)
136. Moorlag SJCFM, *et al.* 2020. *Cell Rep.* 33:108387. [PubMed](#)
137. Koshida R, *et al.* 2015. *Biochem Biophys Res Commun.* 463: 109-115. [PubMed](#)
138. Textor A, *et al.* 2014. *Cancer Res.* 74:6769. [PubMed](#)
139. Frodermann V, *et al.* 2019. *Nat Med.* 25:1761. [PubMed](#)
140. Luong-Gardiol N, *et al.* 2019. *Cancer Cell.* 35:649. [PubMed](#)
141. Murray C, *et al.* 2018. *Lab Chip.* 18:2396. [PubMed](#)
142. Zhao X, *et al.* 2022. *Nat Protoc.* 17:2240. [PubMed](#)
143. Di Martino L, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 13:901. [PubMed](#)
144. Zhang C, *et al.* 2022. *Nat Commun.* 13:3468. [PubMed](#)
145. Lin S, *et al.* 2022. *Nat Commun.* 13:3301. [PubMed](#)
146. Ye P, *et al.* 2022. *Front Cardiovasc Med.* 8:810477. [PubMed](#)
147. Kan X, *et al.* 2015. *Cardiovasc Res.* 10.1093/cvr/cvv255. [PubMed](#)
148. Mizuno T, *et al.* 2017. *Sci Rep.* 7:42714. [PubMed](#)
149. Holokai L, *et al.* 2020. *Cancers (Basel).* 12:00. [PubMed](#)
150. Xiang W, *et al.* 2018. *Nat Commun.* 9:2574. [PubMed](#)
151. LaFleur MW, *et al.* 2019. *Nat Commun.* 10:1668. [PubMed](#)
152. He J, *et al.* 2019. *J Clin Invest.* 130. [PubMed](#)
153. Huang Y, *et al.* 2019. *Cancer Cell.* 35:677. [PubMed](#)
154. Ruiz de Azua I, *et al.* 2017. *J Clin Invest.* 127:4148. [PubMed](#)
155. Zhang H, *et al.* 2019. *Mol Cell.* 76:110. [PubMed](#)
156. Liang J, *et al.* 2020. *Sci Adv.* 6:eabc3646. [PubMed](#)
157. Haas MS, *et al.* 2020. *Mol Cancer Res.* 19:717. [PubMed](#)
158. Jorapur A, *et al.* 2022. *PLoS Pathog.* 18:e1010200. [PubMed](#)
159. Yang Y, *et al.* 2022. *Elife.* 11:. [PubMed](#)
160. Bolkhovitina EL, *et al.* 2022. *Int J Mol Sci.* 23:. [PubMed](#)
161. Colombo M, *et al.* 2022. *iScience.* 25:105042. [PubMed](#)
162. Koikawa K, *et al.* 2021. *Cell.* 184(18):4753-4771.e27. [PubMed](#)
163. Sokol L, *et al.* 2021. *STAR Protocols.* 2(2):100489. [PubMed](#)
164. Yamakawa D, *et al.* 2021. *Cell Reports.* 34(10):108817. [PubMed](#)
165. Troutman TD, *et al.* 2021. *STAR Protocols.* 2(1):100363. [PubMed](#)
166. Wang L, *et al.* 2012. *PLoS One.* 7:e40056. [PubMed](#)
167. Staschke K, *et al.* 2009. *J Immunol.* 183:568. [PubMed](#)
168. Challa TD, *et al.* 2020. *Cell Reports.* 30(10):3424-3433. [PubMed](#)
169. Minuesa G, *et al.* 2019. *Nat Commun.* 10:2691. [PubMed](#)
170. Zhou J, *et al.* 2019. *Nat Commun.* 10:2427. [PubMed](#)
171. Kubota S, *et al.* 2019. *Nat Commun.* 10:1653. [PubMed](#)
172. Wang Q, *et al.* 2018. *Int J Biol Sci.* 14:147. [PubMed](#)
173. Perez-Garcia CG, *et al.* 2022. *Mol Ther Nucleic Acids.* 28:87. [PubMed](#)
174. Uslu M, *et al.* 2020. *J Cell Physiol.* 235:9644. [PubMed](#)
175. Zhai K, *et al.* 2021. *Nat Cancer.* 2:1136. [PubMed](#)
176. Chiang HY, *et al.* 2022. *Nat Commun.* 13:874. [PubMed](#)
177. Rashid MH, *et al.* 2021. *Oncol Rep.* 45:1171. [PubMed](#)
178. Bermejo-Jambrina M, *et al.* 2021. *EMBO J.* 40:e106765. [PubMed](#)
179. Henrich IC, *et al.* 2021. *Cancer Res.* 81:2171. [PubMed](#)
180. Langhauser F, *et al.* 2014. *Stroke.* 45:1799. [PubMed](#)
181. Garcia-Bonilla L, *et al.* 2014. *J Immunol.* 193:2531. [PubMed](#)
182. Favuzzi E, *et al.* 2021. *Cell.* 184(15):4048-4063.e32. [PubMed](#)
183. Hsu Y, *et al.* 2017. *Biochem Biophys Res Commun.* 10.1016/j.bbrc.2017.10.067. [PubMed](#)
184. Subramanian K, *et al.* 2019. *Nat Microbiol.* 4:62. [PubMed](#)
185. Yang BH, *et al.* 2020. *Cell Reports.* 27(12):3629-3645.e6. [PubMed](#)
186. Gomez-Ospina N, *et al.* 2019. *Nat Commun.* 3.225694444. [PubMed](#)
187. Tao Z, *et al.* 2019. *Clin Cancer Res.* 25:1113. [PubMed](#)
188. Tan S, *et al.* 2006. *J Immunol.* 176:2872. [PubMed](#)
189. Roy AG, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
190. Liu S, *et al.* 2022. *J Neuroinflammation.* 19:35. [PubMed](#)
191. Xiao Y, *et al.* 2022. *Nat Commun.* 13:758. [PubMed](#)
192. Ali S, *et al.* 2021. *PLoS One.* 16:e0246646. [PubMed](#)
193. Nuro-Gyina PK, *et al.* 2021. *J Immunol.* 207:868. [PubMed](#)
194. Babagana M, *et al.* 2021. *Aging (Albany NY).* 13:19207. [PubMed](#)
195. Li Q, *et al.* 2022. *Front Cardiovasc Med.* 9:872102. [PubMed](#)
196. Dungan CM, *et al.* 2022. *Aging Cell.* 21:e13528. [PubMed](#)
197. Li T, *et al.* 2021. *J Neuroinflammation.* 81:18. [PubMed](#)
198. Guo M, *et al.* 2020. *Brain.* 147:143. [PubMed](#)
199. Houben T, *et al.* 2020. *J Pathol.* 251:429. [PubMed](#)
200. Cai Z, *et al.* 2020. *Cell Rep.* 31:107816. [PubMed](#)
201. Li L, *et al.* 2014. *J Immunol.* 192:1034. [PubMed](#)
202. Demers M, *et al.* 2012. *Proc Natl Acad Sci U S A.* 109:13076. [PubMed](#)
203. Gladow N, *et al.* 2020. *PLoS One.* 15:e0227734. [PubMed](#)
204. Yuan X, *et al.* 2017. *Elife.* 6:e29540. [PubMed](#)

205. Li YT, *et al.* 2019. *Elife*. 8:e47642. [PubMed](#)
206. Luck H, *et al.* 2019. *Nat Commun*. 10:3650. [PubMed](#)
207. Xiao G, *et al.* 2018. *Cell*. 173:470. [PubMed](#)
208. Spangenberg E, *et al.* 2019. *Nat Commun*. 10:3758. [PubMed](#)
209. Wu ZJ, *et al.* 2018. *Int J Oncol*. 52:1209. [PubMed](#)
210. Szeifert V, *et al.* 2021. *Front Immunol*. 12:671995. [PubMed](#)
211. Wang W, *et al.* 2021. *J Am Heart Assoc*. 10:e019142. [PubMed](#)
212. Berghoff SA, *et al.* 2021. *Nat Neurosci*. 24:47. [PubMed](#)
213. Cao W, *et al.* 2021. *Int J Mol Sci*. 22:. [PubMed](#)
214. Calle P, *et al.* 2021. *Cells*. 10:. [PubMed](#)
215. Ding H, *et al.* 2016. *Nat Commun*. 7:11533. [PubMed](#)
216. Yuan Y, *et al.* 2020. *Front Physiol*. 0.9673611111. [PubMed](#)
217. Varikuti S, *et al.* 2020. *Br J Cancer*. 122:1005. [PubMed](#)
218. Toyohara T, *et al.* 2020. *Cell Stem Cell*. 27:147. [PubMed](#)
219. Bennett FC, *et al.* 2018. *Neuron*. 98:1170. [PubMed](#)
220. Zhang T, *et al.* 2018. *PLoS One*. 13:e0196571. [PubMed](#)
221. Eisemann T, *et al.* 2019. *Front Oncol*. 9:187. [PubMed](#)
222. Cá B, *et al.* 2019. *Front Microbiol*. 1.876388889. [PubMed](#)
223. Dong Y, *et al.* 2021. *Commun Biol*. 4:560. [PubMed](#)
224. Scheiblich H, *et al.* 2021. *Cell*. 184:5089. [PubMed](#)
225. Tomimatsu M, *et al.* 2022. *Sci Rep*. 12:16656. [PubMed](#)
226. Yokomizo-Nakano T, *et al.* 2020. *Cancer Res*. 80:2523. [PubMed](#)
227. Lin KH, *et al.* 2020. *Nat Genet*. 52:408. [PubMed](#)
228. Jablonski K, *et al.* 2015. *PLoS One*. 10: 0145342. [PubMed](#)
229. Sanders K, *et al.* 2015. *Cancer Immunol Res*. 3: 891-901. [PubMed](#)
230. Yuan C, *et al.* 2015. *Biochem Biophys Res Commun*. 464: 249-255. [PubMed](#)
231. Resende M, *et al.* 2013. *J Immunol*. 191:262. [PubMed](#)
232. Muri J, *et al.* 2020. *Cell Reports*. 29(9):2731-2744.e4.. [PubMed](#)
233. Liu Y, *et al.* 2019. *Sci Rep*. 9:18970. [PubMed](#)
234. Clemente-Casares X, *et al.* 2017. *Immunity*. 47:974. [PubMed](#)
235. Gerdes P, *et al.* 2022. *Nat Commun*. 13:7470. [PubMed](#)
236. Dükling T, *et al.* 2022. *Sci Adv*. 8:eabo7639. [PubMed](#)
237. Wang X, *et al.* 2021. *Cell*. 184:5357. [PubMed](#)
238. Li Y, *et al.* 2020. *Theranostics*. 10:2897. [PubMed](#)
239. Xia D, *et al.* 2022. *Mol Neurodegener*. 17:41. [PubMed](#)
240. Koide S, *et al.* 2022. *iScience*. 25:103603. [PubMed](#)
241. Lin T, *et al.* 2021. *PLoS Pathog*. 17:e1009557. [PubMed](#)
242. Casselli T, *et al.* 2021. *PLoS Pathog*. 17:e1009256. [PubMed](#)
243. Kuo P, *et al.* 2016. *J Am Heart Assoc*. 5: 002610. [PubMed](#)
244. Li K, *et al.* 2020. *Nat Commun*. 4.8444444444. [PubMed](#)
245. Avalle L, *et al.* 2020. *Mol Ther Methods Clin Dev*. 0.793055556. [PubMed](#)
246. Zhou Q, *et al.* 2020. *Nat Immunol*. 1.393055556. [PubMed](#)
247. Wang Z *et al.* 2019. *Cell reports*. 26(5):1273-1285 . [PubMed](#)
248. Schaffenaar FH, *et al.* 2019. *Sci Rep*. 9:17391. [PubMed](#)
249. Chao Y, *et al.* 2020. *Sci Adv*. 6:eaaz4204. [PubMed](#)
250. Nguyen GT, *et al.* 2020. *eLife*. 9:e56656.. [PubMed](#)
251. Hoyer FF, *et al.* 2020. *Immunity*. 51(5):899-914.e7.. [PubMed](#)
252. Rodríguez L, *et al.* 2021. *Biomolecules*. 11: . [PubMed](#)
253. Chen L, *et al.* 2021. *Theranostics*. 11:6668. [PubMed](#)
254. Zhang A, *et al.* 2021. *Theranostics*. 11:3839. [PubMed](#)
255. Zhai T, *et al.* 2020. *Clin Exp Pharmacol Physiol*. 47:677. [PubMed](#)
256. Yang N, *et al.* 2022. *Nat Commun*. 13:2336. [PubMed](#)
257. Saber M, *et al.* 2020. *Eur J Neurosci*. 52:2791. [PubMed](#)
258. Garcia-Bonilla L, *et al.* 2015. *J Neurosci*. 35: 14783 - 14793. [PubMed](#)
259. Baruch K, *et al.* 2015. *EMBO J*. 34: 1816 - 1828. [PubMed](#)
260. Schmidt C, *et al.* 2005. *J Immunol*. 175:2286. [PubMed](#)
261. Danne C *et al.* 2017. *Cell host & microbe*. 22(6):733-745 . [PubMed](#)
262. Luo H, *et al.* 2019. *Cell Rep*. 26:945. [PubMed](#)
263. Bozoglu T, *et al.* 2022. *Adv Sci (Weinh)*. 9:e2103867. [PubMed](#)
264. Shen H, *et al.* 2022. *Nat Commun*. 13:5013. [PubMed](#)
265. Zhang X, *et al.* 2022. *J Exp Clin Cancer Res*. 41:246. [PubMed](#)
266. Zhou Y, *et al.* 2022. *Theranostics*. 12:5488. [PubMed](#)
267. Sheng D, *et al.* 2022. *J Immunother Cancer*. 10:. [PubMed](#)
268. Bahmani B, *et al.* 2021. *Nat Commun*. 12:1999. [PubMed](#)
269. Fielding C, *et al.* 2022. *Nat Commun*. 13:543. [PubMed](#)
270. Hirako N, *et al.* 2014. *PLoS One*. 9:103282. [PubMed](#)
271. Chen Z, *et al.* 2016. *Innate Immunity*. 22: 419 - 432. [PubMed](#)
272. Heyde A, *et al.* 2021. *Cell*. 184(5):1348-1361.e22. [PubMed](#)
273. Evavold CL, *et al.* 2021. *Cell*. 184(17):4495-4511.e19. [PubMed](#)
274. Wu L, *et al.* 2020. *Cancer Immunol Res*. 710:8. [PubMed](#)
275. Wunderlich CM, *et al.* 2018. *Nat Commun*. 9:1646. [PubMed](#)
276. Arima Y *et al.* 2017. *eLife*. 6 pii: e25517. [PubMed](#)
277. Hong Y, *et al.* 2019. *J Extracell Vesicles*. 8:1670893. [PubMed](#)
278. Zhang M, *et al.* 2019. *Autophagy*. 1.423611111. [PubMed](#)
279. Wang K, *et al.* 2021. *Nat Commun*. 12:4558. [PubMed](#)
280. Henkle TR, *et al.* 2021. *Cancer Res*. 81:4560. [PubMed](#)
281. Gawish R, *et al.* 2022. *Elife*. 11:. [PubMed](#)
282. Wang T, *et al.* 2022. *Int J Nanomedicine*. 17:2191. [PubMed](#)
283. Nabekura T, *et al.* 2020. *Immunity*. 96:52. [PubMed](#)
284. Wong PP, *et al.* 2020. *Cell*. 181(6):1346-1363.e21. [PubMed](#)

285. Guo S, *et al.* 2021. *Frontiers in Immunology*. 11:614667. [PubMed](#)
 286. Scharenberg SG, *et al.* 2020. *Nat Commun*. 2:76875. [PubMed](#)
 287. K K, *et al.* 2016. *Haematologica*. 151159. [PubMed](#)
 288. Han J, *et al.* 2015. *Cancer Res*. 75: 5273 - 5282. [PubMed](#)
 289. Cai W, *et al.* 2019. *J Neuroinflammation*. 0.788194444. [PubMed](#)
 290. Fernando N, *et al.* 2020. *Front Cell Dev Biol*. 0.691666667. [PubMed](#)
 291. Dougan M, *et al.* 2018. *Cancer Immunol Res*. 6:389. [PubMed](#)
 292. Abdel Malik R, *et al.* 2017. *Circ Res*. 120:99. [PubMed](#)
 293. Saber M, *et al.* 2021. *J Neurotrauma*. 38:2862. [PubMed](#)
 294. Sethuraman SN, *et al.* 2020. *Theranostics*. 10:3397. [PubMed](#)
 295. Zhang SJ, *et al.* 2021. *Adv Sci (Weinh)*. 8:2003410. [PubMed](#)
 296. Steinmetz TD, *et al.* 2021. *Autophagy*. 17:2238. [PubMed](#)
 297. Hohsfield LA, *et al.* 2021. *Elife*. 10:. [PubMed](#)
 298. Kaya-Tilki E, *et al.* 2021. *PLoS One*. 16:e0260633. [PubMed](#)
 299. Zhang J, *et al.* 2021. *Stem Cell Res Ther*. 12:579. [PubMed](#)
 300. Amend A, *et al.* 2021. *Int J Mol Sci*. 22:. [PubMed](#)
 301. Rana MN, *et al.* 2021. *Front Pharmacol*. 12:643215. [PubMed](#)

RRID AB_312790 (BioLegend Cat. No. 101207)
 AB_312791 (BioLegend Cat. No. 101208)

Antigen Details

Structure	Integrin family, associates with integrin β_2 (CD18), 170 kD
Distribution	Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells
Function	Adhesion, chemotaxis
Ligand/Receptor	ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type	B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Coxon A, <i>et al.</i> 1996. <i>Immunity</i> 5:653.
Gene ID	16409 3684


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


Other Formats

APC anti-mouse/human CD11b, Biotin anti-mouse/human CD11b, FITC anti-mouse/human CD11b, PE anti-mouse/human CD11b, PE/Cyanine5 anti-mouse/human CD11b, Purified anti-mouse/human CD11b, PE/Cyanine7 anti-mouse/human CD11b, Alexa Fluor® 488 anti-mouse/human CD11b, Alexa Fluor® 647 anti-mouse/human CD11b, Alexa Fluor® 700 anti-mouse/human CD11b, Pacific Blue™ anti-mouse/human CD11b, APC/Cyanine7 anti-mouse/human CD11b, PerCP/Cyanine5.5 anti-mouse/human CD11b, PerCP anti-mouse/human CD11b, Brilliant Violet 421™ anti-mouse/human CD11b, Brilliant Violet 570™ anti-mouse/human CD11b, Brilliant Violet 605™ anti-mouse/human CD11b, Brilliant Violet 650™ anti-mouse/human CD11b, Brilliant Violet 711™ anti-mouse/human CD11b, Brilliant Violet 785™ anti-mouse/human CD11b, Brilliant Violet 510™ anti-mouse/human CD11b, Ultra-LEAF™ Purified anti-mouse/human CD11b, Purified anti-mouse/human CD11b (Maxpar® Ready), Alexa Fluor® 594 anti-mouse/human CD11b, PE/Dazzle™ 594 anti-mouse/human CD11b, APC/Fire™ 750 anti-mouse/human CD11b, TotalSeq™-A0014 anti-mouse/human CD11b, Brilliant Violet 750™ anti-mouse/human CD11b, TotalSeq™-B0014 anti-mouse/human CD11b, TotalSeq™-C0014 anti-mouse/human CD11b, Spark NIR™ 685 anti-mouse/human CD11b, PE/Fire™ 640 anti-mouse/human CD11b, Spark YG™ 593 anti-mouse/human CD11b, Spark YG™ 570 anti-mouse/human CD11b, PE/Fire™ 810 anti-mouse/human CD11b, APC/Fire™ 810 anti-mouse/human CD11b Antibody, Spark Blue™ 550 anti-mouse/human CD11b, Spark UV™ 387 anti-mouse/human CD11b

Product Data



C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram) (gated on total cells).



Fixed whole mount mouse spleen was stained with Alexa Fluor[®] 488 F4/80 (red) (clone BM8), Brilliant Violet 421[™] CD3 ϵ (green) (clone 145-2C11), and PE CD11b (blue) (clone M1/70). Isotype controls at the same concentrations were used for the negative control. Cells were mounted in Prolong Gold and imaged with a Leica SP8 confocal. Image courtesy of Grzegorz Chodaczek and Zbigniew Mikulski at LIAI.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587